We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+9.28%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$612M
AUM Growth
-$64.3M
Cap. Flow
-$69.2M
Cap. Flow %
-11.31%
Top 10 Hldgs %
55.01%
Holding
54
New
9
Increased
9
Reduced
21
Closed
8

Top Buys

1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$14.4M
2
IART icon
Integra LifeSciences
IART
+$12.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$12.1M
4
MDCO
Medicines Co
MDCO
+$11.3M
5
ADMA icon
ADMA Biologics
ADMA
+$3.08M

Top Sells

1
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
2
CORI
Corium International, Inc.
CORI
+$10.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$9.16M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.72M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$6.07M

Sector Composition

1 Healthcare 91.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$44.7M 7.3%
2,447,746
-43,055
-2% -$668K
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$44.1M 7.2%
3,018,021
-79,943
-3% -$1.12M
HRTX icon
3
Heron Therapeutics
HRTX
$89.1M
$36.7M 6%
2,028,518
-1,427,192
-41% -$23.3M
TVTX icon
4
Travere Therapeutics
TVTX
$5.27B
$34.6M 5.65%
1,641,868
-75,090
-4% -$1.72M
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$33.1M 5.42%
1,029,866
-28,272
-3% -$924K
CORI
6
DELISTED
Corium International, Inc.
CORI
$33M 5.39%
3,432,326
-1,004,400
-23% -$10.7M
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
$30.7M 5.02%
1,150,119
-344,283
-23% -$5.59M
ANGO icon
8
AngioDynamics
ANGO
$558M
$28.8M 4.71%
1,732,361
-38,579
-2% -$658K
CPRX icon
9
Catalyst Pharmaceutical
CPRX
$27.8M 4.54%
7,097,300
+204,800
+3% +$677K
SBBP
10
DELISTED
Strongbridge Biopharma plc.
SBBP
$23.1M 3.78%
3,186,695
+299,900
+10% +$1.87M
PETX
11
DELISTED
Aratana Therapeutics, Inc.
PETX
$22.6M 3.69%
4,294,426
-890,516
-17% -$5.45M
SCTL
12
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$22.5M 3.68%
2,716,168
-740,428
-21% -$6.07M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$21.3M 3.47%
2,591,721
-976,401
-27% -$9.16M
ENDP
14
DELISTED
Endo International plc
ENDP
$18.9M 3.09%
2,442,323
-569,000
-19% -$4.26M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.23B
$18.7M 3.06%
2,340,611
-147,011
-6% -$1.18M
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$18.3M 2.99%
457,080
+316,126
+224% +$12.1M
GWPH
17
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$16.2M 2.65%
+122,930
New +$14.4M
IART icon
18
Integra LifeSciences
IART
$1.5B
$15.8M 2.59%
330,600
+252,100
+321% +$12.3M
BDSI
19
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$13.7M 2.23%
4,634,119
+223,253
+5% +$617K
MDCO
20
DELISTED
Medicines Co
MDCO
$10M 1.64%
+366,300
New +$11.3M
ATRS
21
DELISTED
Antares Pharma, Inc.
ATRS
$9.03M 1.48%
4,535,647
+1,329,747
+41% +$2.89M
NTUS
22
DELISTED
Natus Medical Inc
NTUS
$7.81M 1.28%
204,400
– –
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.27M 1.19%
406,207
– –
TLGT
24
DELISTED
Teligent, Inc
TLGT
$6.99M 1.14%
192,542
+50,000
+35% +$2.39M
NVLN
25
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.08M 0.99%
1,948,554
– –
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Broadfin Capital held 54 positions worth $612M, down 9.5% from $676M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $69.2M in Q4 2017, closing 8 positions and reducing 21 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $8.72M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $16.2M.

  • Broadfin Capital's largest Q4 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 122,930 shares worth $16.2M.
  • Broadfin Capital added most to Integra LifeSciences in Q4 2017, an estimated $12.3M increase.
  • Broadfin Capital's biggest Q4 2017 reduction was Heron Therapeutics, cutting an estimated $23.3M.
  • Broadfin Capital fully exited Alnylam Pharmaceuticals in Q4 2017, selling an estimated $8.72M.
  • Broadfin Capital's ten largest holdings make up 55% of its $612M portfolio in Q4 2017.
  • Broadfin Capital opened 9 new positions and closed 8 in Q4 2017.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $612M.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.